- Home
- NDLS vs MIRA Comparison
NDLS vs MIRA Comparison
Compare NDLS & MIRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NDLS | MIRA |
|---|---|---|
| Founded | 1995 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.9M | 33.7M |
| IPO Year | 2013 | 2023 |
Fundamental Metrics
Financial Performance| Metric | NDLS | MIRA |
|---|---|---|
| Price | $0.80 | $1.49 |
| Analyst Decision | Hold | |
| Analyst Count | 1 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 650.6K | 236.6K |
| Earning Date | 11-05-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $494,087,000.00 | N/A |
| Revenue This Year | $2.29 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.55 | $0.73 |
| 52 Week High | $1.74 | $2.45 |
Technical Indicators
Market Signals| Indicator | NDLS | MIRA |
|---|---|---|
| Relative Strength Index (RSI) | 59.29 | 47.30 |
| Support Level | $0.69 | $1.44 |
| Resistance Level | $0.81 | $1.51 |
| Average True Range (ATR) | 0.06 | 0.07 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 93.35 | 12.04 |
Price Performance
Historical ComparisonAbout NDLS Noodles & Company
Noodles & Co is a restaurant concept offering lunch and dinner within the fast-casual segment of the restaurant industry. The company's menu includes a variety of cooked-to-order dishes, including noodles and pasta, soups, salads and appetizers. The company also provides dining, pick-up and delivery services.
About MIRA MIRA Pharmaceuticals Inc.
Mira Pharmaceuticals Inc is a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a broad range of neurologic and neuropsychiatric disorders. The company's novel oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia.